Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy

Wen Jui Lee, Li Ching Chen, Juo Han Lin, Tzu Chun Cheng, Ching Chuan Kuo, Chih Hsiung Wu, Hui Wen Chang, Shih Hsin Tu, Yuan Soon Ho

研究成果: 雜誌貢獻文章

摘要

Neuroblastoma is the second most common pediatric malignancy and has a high rate of spontaneous remission. Uncovering the mechanisms underlying neuroblastoma cell differentiation is critical for therapeutic purposes. A neuroblastoma cell line (N2a) treated with either serum withdrawal (<2.5%) or melatonin (>0.1 nmol/L) for 24 hours was used as a cell differentiation research model. Interestingly, the hyaluronan synthase 3 (HAS3) protein was induced in differentiated N2a cells. N2a-allografted nude mice received an intraperitoneal injection of melatonin (40 or 80 mg/kg/day for 3 weeks). The mean tumor volume in mice treated with 80 mg/kg melatonin was smaller than that in PBS-treated mice (1416.3 and 3041.3 mm3, respectively, difference = 1625 mm3, *P = 0.0003, n = 7 per group). Compared with the vector control group, N2a cells with forced HAS3 overexpression showed significantly increased neuron length (*P = 0.00082) and neurite outgrowth (*P = 0.00059). Intracellular changes in autophagy, including distorted mitochondria with abnormal circular inner membranes, were detected by transmission electron microscopy (TEM). Our study demonstrated that HAS3-mediated signaling activated by physiological concentrations of melatonin (>0.1 nmol/L) triggered significant N2a cell differentiation. These results provide molecular data with potential clinical relevance for therapeutic drug development.

原文英語
頁(從 - 到)4821-4835
頁數15
期刊Cancer Medicine
8
發行號10
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Mitochondrial Degradation
Melatonin
Neuroblastoma
Cell Differentiation
Spontaneous Remission
Autophagy
Tumor Burden
Intraperitoneal Injections
Transmission Electron Microscopy
Nude Mice
Mitochondria
Pediatrics
Neurons
Cell Line
Control Groups
Membranes
Therapeutics
Serum
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

引用此文

Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy. / Lee, Wen Jui; Chen, Li Ching; Lin, Juo Han; Cheng, Tzu Chun; Kuo, Ching Chuan; Wu, Chih Hsiung; Chang, Hui Wen; Tu, Shih Hsin; Ho, Yuan Soon.

於: Cancer Medicine, 卷 8, 編號 10, 01.01.2019, p. 4821-4835.

研究成果: 雜誌貢獻文章

Lee, Wen Jui ; Chen, Li Ching ; Lin, Juo Han ; Cheng, Tzu Chun ; Kuo, Ching Chuan ; Wu, Chih Hsiung ; Chang, Hui Wen ; Tu, Shih Hsin ; Ho, Yuan Soon. / Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy. 於: Cancer Medicine. 2019 ; 卷 8, 編號 10. 頁 4821-4835.
@article{3fe91ada7dbd47178a3a40453fde4c9b,
title = "Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy",
abstract = "Neuroblastoma is the second most common pediatric malignancy and has a high rate of spontaneous remission. Uncovering the mechanisms underlying neuroblastoma cell differentiation is critical for therapeutic purposes. A neuroblastoma cell line (N2a) treated with either serum withdrawal (<2.5{\%}) or melatonin (>0.1 nmol/L) for 24 hours was used as a cell differentiation research model. Interestingly, the hyaluronan synthase 3 (HAS3) protein was induced in differentiated N2a cells. N2a-allografted nude mice received an intraperitoneal injection of melatonin (40 or 80 mg/kg/day for 3 weeks). The mean tumor volume in mice treated with 80 mg/kg melatonin was smaller than that in PBS-treated mice (1416.3 and 3041.3 mm3, respectively, difference = 1625 mm3, *P = 0.0003, n = 7 per group). Compared with the vector control group, N2a cells with forced HAS3 overexpression showed significantly increased neuron length (*P = 0.00082) and neurite outgrowth (*P = 0.00059). Intracellular changes in autophagy, including distorted mitochondria with abnormal circular inner membranes, were detected by transmission electron microscopy (TEM). Our study demonstrated that HAS3-mediated signaling activated by physiological concentrations of melatonin (>0.1 nmol/L) triggered significant N2a cell differentiation. These results provide molecular data with potential clinical relevance for therapeutic drug development.",
keywords = "autophagy, hyaluronan synthase 3, melatonin, N2a cell differentiation, neuroblastoma",
author = "Lee, {Wen Jui} and Chen, {Li Ching} and Lin, {Juo Han} and Cheng, {Tzu Chun} and Kuo, {Ching Chuan} and Wu, {Chih Hsiung} and Chang, {Hui Wen} and Tu, {Shih Hsin} and Ho, {Yuan Soon}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cam4.2389",
language = "English",
volume = "8",
pages = "4821--4835",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Melatonin promotes neuroblastoma cell differentiation by activating hyaluronan synthase 3-induced mitophagy

AU - Lee, Wen Jui

AU - Chen, Li Ching

AU - Lin, Juo Han

AU - Cheng, Tzu Chun

AU - Kuo, Ching Chuan

AU - Wu, Chih Hsiung

AU - Chang, Hui Wen

AU - Tu, Shih Hsin

AU - Ho, Yuan Soon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Neuroblastoma is the second most common pediatric malignancy and has a high rate of spontaneous remission. Uncovering the mechanisms underlying neuroblastoma cell differentiation is critical for therapeutic purposes. A neuroblastoma cell line (N2a) treated with either serum withdrawal (<2.5%) or melatonin (>0.1 nmol/L) for 24 hours was used as a cell differentiation research model. Interestingly, the hyaluronan synthase 3 (HAS3) protein was induced in differentiated N2a cells. N2a-allografted nude mice received an intraperitoneal injection of melatonin (40 or 80 mg/kg/day for 3 weeks). The mean tumor volume in mice treated with 80 mg/kg melatonin was smaller than that in PBS-treated mice (1416.3 and 3041.3 mm3, respectively, difference = 1625 mm3, *P = 0.0003, n = 7 per group). Compared with the vector control group, N2a cells with forced HAS3 overexpression showed significantly increased neuron length (*P = 0.00082) and neurite outgrowth (*P = 0.00059). Intracellular changes in autophagy, including distorted mitochondria with abnormal circular inner membranes, were detected by transmission electron microscopy (TEM). Our study demonstrated that HAS3-mediated signaling activated by physiological concentrations of melatonin (>0.1 nmol/L) triggered significant N2a cell differentiation. These results provide molecular data with potential clinical relevance for therapeutic drug development.

AB - Neuroblastoma is the second most common pediatric malignancy and has a high rate of spontaneous remission. Uncovering the mechanisms underlying neuroblastoma cell differentiation is critical for therapeutic purposes. A neuroblastoma cell line (N2a) treated with either serum withdrawal (<2.5%) or melatonin (>0.1 nmol/L) for 24 hours was used as a cell differentiation research model. Interestingly, the hyaluronan synthase 3 (HAS3) protein was induced in differentiated N2a cells. N2a-allografted nude mice received an intraperitoneal injection of melatonin (40 or 80 mg/kg/day for 3 weeks). The mean tumor volume in mice treated with 80 mg/kg melatonin was smaller than that in PBS-treated mice (1416.3 and 3041.3 mm3, respectively, difference = 1625 mm3, *P = 0.0003, n = 7 per group). Compared with the vector control group, N2a cells with forced HAS3 overexpression showed significantly increased neuron length (*P = 0.00082) and neurite outgrowth (*P = 0.00059). Intracellular changes in autophagy, including distorted mitochondria with abnormal circular inner membranes, were detected by transmission electron microscopy (TEM). Our study demonstrated that HAS3-mediated signaling activated by physiological concentrations of melatonin (>0.1 nmol/L) triggered significant N2a cell differentiation. These results provide molecular data with potential clinical relevance for therapeutic drug development.

KW - autophagy

KW - hyaluronan synthase 3

KW - melatonin

KW - N2a cell differentiation

KW - neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=85071284753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071284753&partnerID=8YFLogxK

U2 - 10.1002/cam4.2389

DO - 10.1002/cam4.2389

M3 - Article

C2 - 31274246

AN - SCOPUS:85071284753

VL - 8

SP - 4821

EP - 4835

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 10

ER -